CoChat
Sign Up
Cited by 410

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis

MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., Degenhardt, L., Hickman, M.·2012·BMJ
DOI 10.1136/bmj.e5945PMC PMC3489107
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.e5945

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Selection of studies directly investigating impact of opiate substitution treatment on HIV transmission
Fig 1 Selection of studies directly investigating impact of opiate substitution treatment on HIV transmissionCC BY-NC · PubMed Central
Fig 2 Selection of prospective cohort studies relating to HIV incidence in people who inject drugs. Of seven identified, two were included in sensitivity or subgroup analyses only
Fig 2 Selection of prospective cohort studies relating to HIV incidence in people who inject drugs. Of seven identified, two were included in sensitivity or subgroup analyses onlyCC BY-NC · PubMed Central
Fig 3 Meta-analysis of studies showing impact of opiate substitution treatment in relation to HIV transmission in people who inject drugs among all pooled studies and studies reporting only adjusted effect estimates
Fig 3 Meta-analysis of studies showing impact of opiate substitution treatment in relation to HIV transmission in people who inject drugs among all pooled studies and studies reporting only adjusted effect estimatesCC BY-NC · PubMed Central
Fig 4 Impact of opiate substitution treatment in relation to HIV incidence among people who inject drugs by geographical region
Fig 4 Impact of opiate substitution treatment in relation to HIV incidence among people who inject drugs by geographical regionCC BY-NC · PubMed Central
Fig 5 Impact of opiate substitution treatment in relation to HIV incidence among people who inject drugs by site of recruitment of study participants
Fig 5 Impact of opiate substitution treatment in relation to HIV incidence among people who inject drugs by site of recruitment of study participantsCC BY-NC · PubMed Central
Fig 6 Meta-analysis of included studies showing impact of detoxification treatment on incident HIV infection among people who inject drugs compared with either no treatment or methadone maintenance treatment
Fig 6 Meta-analysis of included studies showing impact of detoxification treatment on incident HIV infection among people who inject drugs compared with either no treatment or methadone maintenance treatmentCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 64

  1. [1]UNAIDS, Health Canada, Open Society Institute, Canadian International Development Agency. The Warsaw declaration: a framework for effective action on HIV/AIDS and injecting drug use. Second international policy dialogue on HIV/AIDS. 2003. 15104064
  2. [2]Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; 376: 268-84. 20650523 PMC6464374
  3. [3]Bruneau J, Daniel M, Abrahamowicz M, Zang G, Lamothe F, Vincelette J. Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in Montreal, Canada: A 16-year longitudinal study. Am J Epidemiol 2011; 173: 1049-58. 21362739 PMC3121223
  4. [4]Rhodes T, Ball A, Stimson GV, Kobyshcha Y, Fitch C, Pokrovsky V, et al. HIV infection associated with drug injecting in the newly independent states, eastern Europe: the social and economic context of epidemics. Addiction 1999; 94: 1323-6. 10615718
  5. [5]Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733-45. 18817968
  6. [6]Wiessing L, van de Laar MJ, Donoghoe MC, Guarita B, Klempova D, Griffiths P. HIV among injecting drug users in Europe: increasing trends in the East. Euro Surveill 2008; 13: 19067. 19087869
  7. [7]Wiessing L, Likatavicius G, Hedrich D, Guarita B, van den Laar MJ, Vicente J. Trends in HIV and hepatitis c virus infections among injecting drug users in Europe, 2005-2010. Euro Surveill 2011; 16: 20031. 22172300
  8. [8]Nelson KE, Galai N, Safaeian M, Strathdee SA, Celentano DD, Vlahov D. Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am Epidemiol 2002; 156: 641-53. 12244033
  9. [9]Des Jarlais DC, Marmor M, Friedmann P, Titus S, Aviles E, Deren S, et al. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Pub Health 2000;90: 352-9. PMC1446171 10705851
  10. [11]Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, Des Jarlais DC, et al. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS 2001; 15: 397-405. 11273220
  11. [12]Rhodes T, Lowndes C, Judd A, Mikhailova LA, Sarang A, Rylkov A, et al. Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS 2002; 16: F25-31. 12218407
  12. [13]Skidmore CA, Robertson JR, Savage G. Mortality and increasing drug use in Edinburgh: implications for HIV epidemic. Scott Med J 1990; 35: 100-2. 2237384
  13. [14]Uuskula A, McNutt L, Dehovitz J, Fischer K, Heimer R. High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia. Int J STD AIDS 2007; 18: 41-6. 17326862 PMC2925660
  14. [15]Sharma M, Oppenheimer E, Saidel T, Loo V, Garg R. A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region. AIDS 2009; 23: 1405-13. 19579290
  15. [16]Farrell M, Wodak A, Gowing L. Maintenance drugs to treat opioid dependence. BMJ 2012; 344: e2823. 22589497
  16. [17]Suntharasamai P, Martin M, Vanichseni S, Van GF, Mock PA, Pitisuttithum P, et al. Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction 2009; 104: 235-42. 19149819
  17. [18]Malta M, Strathdee SA, Magnanini MMF, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review. Addiction 2008; 103: 1242-57. 18855813
  18. [21]Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011; 8: CD004145. 21833948 PMC13650978
  19. [22]Degenhardt L, Bucello C, Mathers B, Briegleb C, Hammad A, Hickman M. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2010; 106: 32-51. 21054613
  20. [23]Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 1014-028. 20189638
  21. [24]Schaub M, Subata E, Chtenguelov V, Weiler G, Uchtenhagen A. Feasibility of buprenorphine maintenance therapy programs in the Ukraine: first promising treatment outcomes. Eur Addict Res 2009; 15: 157-62. 19420948
  22. [25]Yin W, Hao Y, Sun X, Gong X, Li F, Li J, et al. Scaling up the national methadone maintenance treatment program in China: achievements and challenges. Int J Epidemiol 2010; 39: ii37. PMC2992615 21113034
  23. [26]Kumar MS, Agrawal A. Scale up of opioid substitution therapy in India: opportunities and challenges. Int J Drug Pol 2012; 23: 169-71. 22280919
  24. [27]Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 2000; 59: 17-31. 10706972
  25. [31]Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. 9310563 PMC2127453
  26. [32]Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 1690-1. 9832001
  27. [34]Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. Am J Public Health 1998; 88: 34-9. 9584030 PMC1508390
  28. [35]Peters AD, Reid MM. Methadone treatment in the Scottish context: outcomes of a community-based service for drug users in Lothian. Drug Alcohol Depend 1998; 50: 47-55. 9589272
  29. [36]McFarland W, Kellogg TA, Louie B, Murrill C, Katz MH. Low estimates of HIV seroconversions among clients of a drug treatment clinic in San Francisco, 1995 to 1998. J Acquir Immune Defic Syndr 2000; 23: 426-9. 10866236
  30. [37]Kerr T, Stoltz J-A, Strathdee S, Li K, Hogg RS, Montaner JS, et al. The impact of sex partners’ HIV status on HIV seroconversion in a prospective cohort of injection drug users. J Acquir Immune Defic Syndr 2006; 41: 119-123. 16340484
  31. [38]Ruan Y, Qin G, Yin L, Chen K, Qian H-Z, Hao C, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS 2007;21(suppl 8): S39-46. 18172390
  32. [39]Chitwood DD, Griffin DK, Comerford M, Page JB, Trapido EJ, Lai S, et al. Risk factors for HIV-1 seroconversion among injection drug users: a case-control study. Am J Public Health 1995; 85: 1538-42. 7485667 PMC1615687
  33. [40]Bruandet A, Lucidarme D, Decoster A, Ilef D, Harbonnier J, Jacob C, et al. Incidence and risk factors of hcv infection in a cohort of intravenous drug users in the north and east of france. Rev Epidemiol Sante Publique 2006; 54: 1S15-22. 17073126
  34. [41]Smyth BP, O’Connor JJ, Barry J, Keenan E. Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin. J Epidemiol Community Health 2003; 57: 310-1. 12646549 PMC1732426
  35. [42]Van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ 1998; 317: 433-7. 9703523 PMC28635
  36. [43]Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994; 8: 223-31. 8043227
  37. [44]Metzger DS, Woody GE, McLellan AT, O’Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6: 1049-56. 8340896
  38. [45]Van den Berg C, Smit C, Van BG, Coutinho R, Prins M, Amsterdam C. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-462. 17697278 PMC2040242
  39. [46]Williams AB, McNelly EA, Williams AE, D’Aquila RT. Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care 1992; 4: 35-41. 1314099
  40. [47]Zangerle R, Fuchs D, Rossler H, Reibnegger G, Riemer Y, Weiss SH, et al. Trends in HIV infection among intravenous drug users in Innsbruck, Austria. J Acquir Immune Defic Syndr 1992; 5: 865-71. 1512685
  41. [48]Serpelloni G, Carrieri MP, Rezza G, Morganti S, Gomma M, Binkin N. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study. AIDS Care 1994; 6: 215-20. 8061081
  42. [49]Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330: 24-5. 15533854 PMC539846
  43. [50]Turner K, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of Hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 1978-88. 21615585
  44. [51]Deren S, Kang SY, Colon HM, Andia JF, Robles RR. HIV incidence among high-risk Puerto Rican drug users: a comparison of East Harlem, New York, and Bayamon, Puerto Rico. J Acquir Immune Defic Syndr 2004; 36: 1067-74. 15247560
  45. [52]Gandhi DH, Jaffe JH, McNary S, Kavanagh GJ, Hayes M, Currens M. Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction 2002; 98: 453-62. 12653815
  46. [53]Teesson M, Ross J, Darke S, Lynskey M, Ali R, Ritter A, et al. One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend 2006; 83: 174-80. 16343809
  47. [54]Liu H, Grusky O, Zhu Y, Li X. Do drug users in China who frequently receive detoxification treatment change their risky drug use practices and sexual behavior? Drug Alcohol Depend 2006; 84: 114-21. 16443333
  48. [56]Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010; 105: 844-59. 20219055
  49. [57]Kitayaporn D, Uneklabh C, Weniger BG, Lohsomboon P, Kaewkungwal J, Morgan WM, et al. HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand. AIDS 1994; 8: 1443-50. 7818815
  50. [58]Rhodes T, Sarang A, Vickerman P, Hickman M. Why Russia must legalise methadone. BMJ 2010; 341: 129-31. 20627977
  51. [59]Celentano DD, Hodge MJ, Razak MH, Beyrer C, Kawichai S, Cegielski JP, et al. HIV-1 incidence among opiate users in northern Thailand. Am J Epidemiol 1999; 149: 15. 10084245
  52. [60]Rhodes T, Platt L, Maximova S, Koshkina E, Latishevskaya N, Hickman M, et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction 2006; 101: 252-66. 16445554
  53. [61]Stachowiak JA, Tishkova FK, Strathdee SA, Stibich MA, Latypov A, Mogilnii V, et al. Marked ethnic differences in HIV prevalence and risk behaviors among injection drug users in Dushanbe, Tajikistan. Drug Alcohol Depend 2004; 82(suppl 1): S7-14. 16769449
  54. [62]Marmot M, Brunner E. Cohort profile: the Whitehall II study. Int J Epidemiol 2004; 34: 251-6. 15576467
  55. [63]Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De AD, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010; 341: c3172. 20595255 PMC2895695
  56. [64]Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study. Addiction 2008; 103: 1828-36.. 18778390
  57. [65]Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84: 188-94. 16542797
  58. [66]Sharma M, Burrows D, Bluthenthal R. Coverage of HIV prevention programmes for injection drug users: confusions, aspirations, definitions and ways forward. Int J Drug Pol 2007; 18: 92-8. PMC1945164 17689351
  59. [67]Wiessing L, Likatavicius G, Klempová D, Hedrich D, Nardone A, et al. Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health 2009; 99: 1049-52. 19372511 PMC2679784
  60. [68]Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic settings. Addiction 2012;May 7; 10.1111/j.1360-0443.2012.03932.x. 22564041 · DOI
  61. [69]Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. Lancet 2010; 376: 285-301. 20650522
  62. [70]Larney S. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction 2010; 105: 216-23. 20078480
  63. [71]Hedrich D, Alves P, Farrell M, Stover H, Moller L, Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction 2011; 107: 501-17. 21955033
  64. [72]Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379: 55-70. 22225671

Cited by

Sorted by citations

See all 410

Metadata

Authors
MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., Degenhardt, L., & Hickman, M.
Venue
BMJ
Publisher
BMJ
Published
2012-10-03
Volume
345
Issue
oct03 3
Pages
e5945-e5945
ISSN
1756-1833
DOI
10.1136/bmj.e5945
PMC
PMC3489107
Cited by
410
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review